At a glance
ClinicalIndex Comparison Record- ✓Stable antiretroviral therapy for at least 12 months
- ✓Plasma HIV RNA < 50 copies/mL at screening, with all values in past year < 50 copies/mL (isolated single values 50-200 allowed)
- ✓≥90% adherence to therapy in preceding 30 days by self-report
- ✕Prior or ongoing use of any integrase inhibitor or R5 inhibitor
- ✕Plan to modify existing antiretroviral therapy in next 24 weeks
- ✕Serious illness requiring hospitalization or parenteral antibiotics within preceding 3 months
- ✕Concurrent or recent exposure to immunomodulatory drugs
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
In Brief
A Phase 3 clinical trial evaluating Maraviroc and placebo for HIV Infection and 3 related conditions. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the potentially beneficial aspects of CCR5 inhibition on inflammation and endothelial function as measured by brachial artery reactivity in antiretroviral treated HIV patients with an undetectable viral load.
Study Details
Timeline
Interventions
For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.